[Additional effect of SERM: mammary gland].
One of selective estrogen receptor modulators (SERMs), tamoxifen, has been widely used for prevention of breast cancer, postoperative adjuvant therapy and treatment of advanced breast cancer. The relation of a long-term administration of tamoxifen and its adverse effects have been extensively investigated. Favorable effects of tamoxifen are:the reduction in the risk of contralateral breast cancer, gain in bone density in postmenopausal women and decrease in serum low-density lipoprotein cholesterol. Unfavorable effects are: gynecologic problems and the increase in the risk of endometrial cancer and thromboembolism. In contrast, another SERM, raloxifene, has reported to have similar favorable adverse effects but no unfavorable effect on endometrium.
Kurebayashi
Junichi
J
Department of Breast & Thyroid Surgery, Kawasaki Medical School.
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D016889:Endometrial Neoplasms / Q000139:chemically induced; D005260:Female; D006801:Humans; D015201:Meta-Analysis as Topic; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013923:Thromboembolism / Q000139:chemically induced
D018931:Antineoplastic Agents, Hormonal; D008078:Cholesterol, LDL; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride